Elevated Risk of Adverse Effects from Foodborne Contaminants and Drugs in Inflammatory Bowel Disease: a Review

Overview

Journal Arch Toxicol

Specialty Toxicology

Date 2024 Sep 9

PMID 39249550

Authors

Tom Walraven

Mathias Busch

Jingxuan Wang

Joanne M Donkers

Marjolijn Duijvestein

Evita van de Steeg

Nynke I Kramer

Hans Bouwmeester

Affiliations

Soon will be listed here.

Abstract

The global burden of Inflammatory bowel disease (IBD) has been rising over the last decades. IBD is an intestinal disorder with a complex and largely unknown etiology. The disease is characterized by a chronically inflamed gastrointestinal tract, with intermittent phases of exacerbation and remission. This compromised intestinal barrier can contribute to, enhance, or even enable the toxicity of drugs, food-borne chemicals and particulate matter. This review discusses whether the rising prevalence of IBD in our society warrants the consideration of IBD patients as a specific population group in toxicological safety assessment. Various in vivo, ex vivo and in vitro models are discussed that can simulate hallmarks of IBD and may be used to study the effects of prevalent intestinal inflammation on the hazards of these various toxicants. In conclusion, risk assessments based on healthy individuals may not sufficiently cover IBD patient safety and it is suggested to consider this susceptible subgroup of the population in future toxicological assessments.

References

Singh S, Blanchard A, Walker J, Graff L, Miller N, Bernstein C . Common symptoms and stressors among individuals with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2011; 9(9):769-75. DOI: 10.1016/j.cgh.2011.05.016. View

dAldebert E, Quaranta M, Sebert M, Bonnet D, Kirzin S, Portier G . Characterization of Human Colon Organoids From Inflammatory Bowel Disease Patients. Front Cell Dev Biol. 2020; 8:363. PMC: 7287042. DOI: 10.3389/fcell.2020.00363. View

Khan M, Howden C . The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders. Gastroenterol Hepatol (N Y). 2018; 14(3):169-175. PMC: 6004044. View

Chen K, Mallon B, McKay R, Robey P . Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics. Cell Stem Cell. 2014; 14(1):13-26. PMC: 3915741. DOI: 10.1016/j.stem.2013.12.005. View

Khanna S, Shin A, Kelly C . Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017; 15(2):166-174. DOI: 10.1016/j.cgh.2016.10.024. View

Shin W, Kim H . Intestinal barrier dysfunction orchestrates the onset of inflammatory host-microbiome cross-talk in a human gut inflammation-on-a-chip. Proc Natl Acad Sci U S A. 2018; 115(45):E10539-E10547. PMC: 6233106. DOI: 10.1073/pnas.1810819115. View

Foong S, Ma N, Lam S, Peng W, Low F, Lee B . A recent global review of hazardous chlorpyrifos pesticide in fruit and vegetables: Prevalence, remediation and actions needed. J Hazard Mater. 2020; 400:123006. DOI: 10.1016/j.jhazmat.2020.123006. View

Kampfer A, Urban P, La Spina R, Jimenez I, Kanase N, Stone V . Ongoing inflammation enhances the toxicity of engineered nanomaterials: Application of an in vitro co-culture model of the healthy and inflamed intestine. Toxicol In Vitro. 2019; 63:104738. PMC: 6961208. DOI: 10.1016/j.tiv.2019.104738. View

Fort M, Lesley R, Davidson N, Menon S, Brombacher F, Leach M . IL-4 exacerbates disease in a Th1 cell transfer model of colitis. J Immunol. 2001; 166(4):2793-800. DOI: 10.4049/jimmunol.166.4.2793. View

10.

Monteiro C, Cannon G, Levy R, Moubarac J, Louzada M, Rauber F . Ultra-processed foods: what they are and how to identify them. Public Health Nutr. 2019; 22(5):936-941. PMC: 10260459. DOI: 10.1017/S1368980018003762. View

11.

Sonis S . The pathobiology of mucositis. Nat Rev Cancer. 2004; 4(4):277-84. DOI: 10.1038/nrc1318. View

12.

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

13.

Pereira C, Coelho R, Gracio D, Dias C, Silva M, Peixoto A . DNA Damage and Oxidative DNA Damage in Inflammatory Bowel Disease. J Crohns Colitis. 2016; 10(11):1316-1323. DOI: 10.1093/ecco-jcc/jjw088. View

14.

Kwon Y, Banskota S, Wang H, Rossi L, Grondin J, Syed S . Chronic exposure to synthetic food colorant Allura Red AC promotes susceptibility to experimental colitis via intestinal serotonin in mice. Nat Commun. 2022; 13(1):7617. PMC: 9768151. DOI: 10.1038/s41467-022-35309-y. View

15.

Lee G . The Balance of Th17 versus Treg Cells in Autoimmunity. Int J Mol Sci. 2018; 19(3). PMC: 5877591. DOI: 10.3390/ijms19030730. View

16.

Estudante M, Morais J, Soveral G, Benet L . Intestinal drug transporters: an overview. Adv Drug Deliv Rev. 2012; 65(10):1340-56. DOI: 10.1016/j.addr.2012.09.042. View

17.

Sellon R, Tonkonogy S, Schultz M, Dieleman L, Grenther W, Balish E . Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998; 66(11):5224-31. PMC: 108652. DOI: 10.1128/IAI.66.11.5224-5231.1998. View

18.

Forrest K, Symmons D, Foster P . Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease?. Aliment Pharmacol Ther. 2004; 20(10):1035-43. DOI: 10.1111/j.1365-2036.2004.02270.x. View

19.

Lian P, Braber S, Varasteh S, Wichers H, Folkerts G . Hypoxia and heat stress affect epithelial integrity in a Caco-2/HT-29 co-culture. Sci Rep. 2021; 11(1):13186. PMC: 8222227. DOI: 10.1038/s41598-021-92574-5. View

20.

Jahnel J, Fickert P, Hauer A, Hogenauer C, Avian A, Trauner M . Inflammatory bowel disease alters intestinal bile acid transporter expression. Drug Metab Dispos. 2014; 42(9):1423-31. DOI: 10.1124/dmd.114.058065. View